View this email in your browser
The Council on Accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care, (AAALAC) has granted Transpharmation's UK Discovery Park facilities full accreditation. 

"AAALAC commends Agenda’s Discovery Park facility for providing and maintaining an excellent programme of laboratory animal care and use."
What does this mean for you?

The AAALAC accreditation reassures clients that the research facilities we use are dedicated to achieving the highest standards for animal care and use, meeting all local and national regulations. The standards go beyond those required by law, assuring Transpharmation's drug developers exceptional standards of work for their in-vivo research needs for our client drug development studies. 
Only 14 establishments in the UK hold
this important accreditation.

This globally recognised accreditation for excellence in animal care, takes into account facilities, policies, veterinary care, animal housing and management. By providing the best across all of these areas, you can be sure that we'll provide you with scientific validity, together with reliable, robust scientific outcomes. We are proud to work alongside Agenda Life Sciences at Discovery Park Research Facilities.
Contact us to book in your preclinical studies wherever you are around the world.
AAALAC is a private not for profit organisation whose purpose is to promote the humane treatment of animals in science by evaluating and accrediting animal care and use programmes.

Come and see us, virtually or in person

With a continuing focus on the advances in science and therapy of Alzheimer’s and Parkinson’s Diseases, and related neurological disorders, we look forward to taking part in the AD/PD annual event later this month.

One of Transpharmation's scientists, Caoimhe Tyndall will be presenting a poster titled Assessing the immunogenicity of alpha-synuclein oligomers, filaments and fibrils in a clinically relevant model of synucleinopathy in-vitro, (poster P529) at our virtual booth. 

||  We will make the poster available to you after the event  ||


InterVivo Solutions, Transpharmation's sister company, will be hosting an in-person booth at this conference in Barcelona.

Whichever you decide to attend, we look forward to seeing you!

***** Read the abstract here! *****
Other news!

Did you know that Transpharmation has merged with InterVivo Solutions? Clients benefit from new avenues for preclinical neuroscience projects with complementary assays, techniques and methodologies.

Wider range of epilepsy and pain services
Cognitive assays across small and large animal
species and models

Increased capabilities for small molecule and protein
bio analysis 

Flexibility to increase capacity across small and large animal species in Europe and North America 

Click here to access merger news in detail
We remain a leading global CRO with a huge range of translational research opportunities for all clients.

For all preclinical study enquiries or to find out how we can help develop your research further, please contact me at any time

Be sure to follow Transpharmation on LinkedIn and keep an eye on our website for up-to-date information.

Wherever you are based around the world, we can work with you.

I look forward to speaking to you soon. Thank you.

Dr.Mark Duxon
CEO of Transpharmation and InterVivo Solutions

Preclinical services:

Psychedelics / Pain / Neuropathic pain / Alzheimer’s Disease / Depression/anxiety / Schizophrenia / Inflammatory pain / Cognitive disorders / Multifocal motor neuropathy (MMN) / Molecular Biomarkers / Sleep/wake / QEEG / ASSR / Cancer and chemotherapy / Neuroinflammation

Copyright © Transpharmation Newsletter March 2022

Our mailing address is:

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.